title: An adjuvanted whole cell vaccine as post-remission immunotherapy for acute leukemia.
abstract: Many acute leukemia patients treated with chemotherapy are at high risk of relapse without allogeneic stem cell transplantation, an immunotherapy that is limited by significant toxicity and donor availability. We propose that post-remission vaccination with a simple autologous whole cell vaccine adjuvanted with α-galactosylceramide may be effective to prevent relapse of acute leukemia.
authors.affiliation: Malaghan Institute of Medical Research , Wellington, New Zealand.
authors.forename: Robert
authors.initials: R
authors.lastname: Weinkove
authors.affiliation: Malaghan Institute of Medical Research , Wellington, New Zealand.
authors.forename: Lindsay R
authors.initials: LR
authors.lastname: Ancelet
authors.affiliation: Malaghan Institute of Medical Research , Wellington, New Zealand ; School of Biological Sciences, Victoria University of Wellington , Wellington, New Zealand.
authors.forename: John D
authors.initials: JD
authors.lastname: Gibbins
authors.affiliation: Malaghan Institute of Medical Research , Wellington, New Zealand ; School of Biological Sciences, Victoria University of Wellington , Wellington, New Zealand.
authors.forename: Ian F
authors.initials: IF
authors.lastname: Hermans
keywords: NKT cell; acute leukemia; immunotherapy; α-galactosylceramide